Immune Response to SARS-CoV-2 Vaccines

Immune Response to SARS-CoV-2 Vaccines

COVID-19 vaccines have been developed to confer immunity against the SARS-CoV-2 infection. Prior to the pandemic of COVID-19 which started in March 2020, there was a well-established understanding about the structure and pathogenesis of previously known Coronaviruses from the SARS and MERS outbreaks...

Full description

Bibliographic Details
Main Authors:	Navya Bellamkonda, Upendra Pradeep Lambe, Sonali Sawant, Shyam Sundar Nandi, Chiranjib Chakraborty, Deepak Shukla
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Biomedicines
Subjects:	COVID-19 SARS-CoV-2 mRNA vaccine adenoviral vectored vaccine inactivated vaccine subunit vaccine
Online Access:	https://www.mdpi.com/2227-9059/10/7/1464

Similar Items

Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
by: Keshav Goyal, et al.
Published: (2021-11-01)

Different T-cell and B-cell repertoire elicited by the SARS-CoV-2 inactivated vaccine and S1 subunit vaccine in rhesus macaques
by: Li Qin, et al.
Published: (2022-11-01)

Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population
by: Mohamed Lounis, et al.
Published: (2022-10-01)

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
by: Ekramy E. Sayedahmed, et al.
Published: (2020-10-01)

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
by: Abdulla Watad, et al.
Published: (2021-04-01)

mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions
by: Ryo Okuyama
Published: (2023-11-01)

mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People
by: Anna Rosa Garbuglia, et al.
Published: (2022-04-01)

High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5
by: Jochen M. Wettengel, et al.
Published: (2024-02-01)

Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters
by: Yongjun Sui, et al.
Published: (2025-02-01)

Impact of Metabolic States on SARS-CoV-2 Vaccine Responses in Mouse Models of Obesity and Diabetes
by: Olivia A. Smith, et al.
Published: (2024-12-01)

Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study
by: Zhi-Qiang Lin, et al.
Published: (2022-04-01)

Synergistic Effect of Co-Administered SARS-CoV-2 Vaccines Improves Immune Responses in BALB/c Mice: A Preliminary Study
by: Nshimirimana Jonas, et al.
Published: (2024-06-01)

Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
by: Chin Shern Lau, et al.
Published: (2022-05-01)

Adenovirus Vaccine Containing Truncated SARS-CoV-2 Spike Protein S1 Subunit Leads to a Specific Immune Response in Mice
by: Keda Chen, et al.
Published: (2023-02-01)

A Disproportionality Analysis for Association of Systemic Capillary Leak Syndrome with COVID-19 Vaccination Using the World Health Organization Pharmacovigilance Database
by: Jin Park, et al.
Published: (2022-05-01)

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2023-05-01)

Corrigendum: Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2024-02-01)

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context
by: Gabriela Tapia-Calle, et al.
Published: (2025-01-01)

Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3
by: Yu-Jing Fan, et al.
Published: (2021-09-01)

Comparative characteristics of COVID-19 vaccines used for mass immunisation
by: G. G. Onishchenko, et al.
Published: (2021-10-01)

Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein
by: Saveliy A. Sheetikov, et al.
Published: (2024-04-01)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
by: Carmine D'Amico, et al.
Published: (2025-03-01)

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization
by: Sansanee Thotsiri, et al.
Published: (2022-10-01)

Analysis of Promising Approaches to COVID-19 Vaccine Development
by: G. G. Onishchenko, et al.
Published: (2020-12-01)

Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice
by: Mariia V. Sergeeva, et al.
Published: (2024-12-01)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
by: Jira Chansaenroj, et al.
Published: (2022-07-01)

Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential
by: G. G. Onishchenko, et al.
Published: (2021-12-01)

Susac Syndrome Following COVID-19 Vaccination: A Case Report
by: Po-Jui Chen, et al.
Published: (2022-02-01)

Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study
by: Ferdi Tanir, et al.
Published: (2022-07-01)

Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters
by: Peter Zhou, et al.
Published: (2024-08-01)

In vitro immune evaluation of adenoviral vector-based platform for infectious diseases
by: Joanna Baran, et al.
Published: (2023-12-01)

An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
by: Dona Susan Mathew, et al.
Published: (2023-10-01)

Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2
by: Anna V. Vakhrusheva, et al.
Published: (2024-10-01)

One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test
by: Yesim Tuyji Tok, et al.
Published: (2023-02-01)

Development of an Inactivated Vaccine against SARS CoV-2
by: Shaikh Terkis Islam Pavel, et al.
Published: (2021-11-01)

Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial
by: Huan Zhou, et al.
Published: (2024-06-01)

Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
by: Saed Abbasi, et al.
Published: (2021-05-01)

SARS-CoV-2 vaccines, where do we stand?
by: Fischer, Alain
Published: (2021-01-01)

Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants
by: Xuesong Xu, et al.
Published: (2022-12-01)